Key statistics
As of last trade Heron Therapeutics Inc (AXD2:FRA) traded at 0.9815, 8.93% above its 52-week low of 0.901, set on Nov 21, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.9815 |
|---|---|
| High | 0.9815 |
| Low | 0.9815 |
| Bid | 0.9485 |
| Offer | 0.981 |
| Previous close | 1.06 |
| Average volume | 3.63k |
|---|---|
| Shares outstanding | 183.36m |
| Free float | 181.82m |
| P/E (TTM) | -- |
| Market cap | 214.53m USD |
| EPS (TTM) | -0.0809 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 07:05 GMT.
More ▼
Announcements
- Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
- Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
- Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
- Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
- Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
More ▼
